| Harmony Biosciences Holdings, Inc. (HRMY) Q1 2025 Earnings Call Transcript |
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY ) Q1 2025 Earnings Call May 6, 2025 8:30 AM ET Company Participants Brennan Doyle - Head, Investor Relations Jeffrey Dayno - President and Chief Executive Officer Adam Zaeske - Chief Commercial Officer Kumar Budur - Chief Medical and Scientific Officer Sandip Kapadia - Chief Financial Officer Conference Call Participants Graig Suvannavejh - Mizuho Securities David Amsellem - Piper Sandler Ami Fadia - Needham Patrick Trucchio - H.C. Wainwright David Hoang - Deutsche Bank Ash Verma - UBS Jason Gerberry - Bank of America Charles Duncan - Cantor Fitzgerald Operator Good morning. |
seekingalpha.com |
2025-05-06 21:05:27 |
Czytaj oryginał (ang.) |
| Harmony Biosciences Holdings, Inc. (HRMY) Tops Q1 Earnings and Revenue Estimates |
Harmony Biosciences Holdings, Inc. (HRMY) came out with quarterly earnings of $0.78 per share, beating the Zacks Consensus Estimate of $0.59 per share. This compares to earnings of $0.67 per share a year ago. |
zacks.com |
2025-05-06 13:50:36 |
Czytaj oryginał (ang.) |
| Harmony Biosciences Reports Strong Q1 2025 Financial Results, Highlights Advancement of Its Pipeline and Upcoming Catalysts, and Reaffirms 2025 Revenue Guidance |
PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced strong year-over-year revenue growth for WAKIX® of 20% in the first quarter 2025, on its way to a potential $1B+ opportunity in narcolepsy alone and poised for additional growth from its next-gen pitolisant development programs. The company has demonstrated four consecutive years of profitability and has grown its cash and investments position to over $600M. “Building off of our strong fou. |
businesswire.com |
2025-05-06 11:30:00 |
Czytaj oryginał (ang.) |
| Why Harmony Biosciences (HRMY) Could Beat Earnings Estimates Again |
Harmony Biosciences (HRMY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report. |
zacks.com |
2025-05-01 17:10:34 |
Czytaj oryginał (ang.) |
| Harmony Biosciences to Report First Quarter 2025 Financial Results on May 6, 2025 |
PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will report first quarter 2025 financial results on Tuesday, May 6, 2025, before the open of the U.S. financial markets. Harmony will host a conference call and webcast on May 6, 2025, at 8:30 a.m. ET to discuss the results. To participate in the call, please dial 800-267-6316 (domestic) or 203-518-9783 (international), and reference passcode HRMYQ125. It is recommended that you dia. |
businesswire.com |
2025-04-29 12:05:00 |
Czytaj oryginał (ang.) |
| JAZZ vs. HRMY: Which Neuroscience Drugmaker Is the Stronger Play? |
Both JAZZ and HRMY expect sales from neuroscience products to grow in 2025. |
zacks.com |
2025-04-21 12:40:38 |
Czytaj oryginał (ang.) |
| Harmony Biosciences Presents Promising Open-Label Extension Data of ZYN002 in Fragile X Syndrome |
PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced the presentation of updated data from its Open-Label Extension (OLE) study (ZYN2-CL-017) evaluating the safety and effectiveness of ZYN002 in children, adolescents, and adults with Fragile X syndrome (FXS). The data showed clinically meaningful improvements in irritability-related symptoms prevalent in individuals with FXS. There are currently no U.S. Food & Drug Administration (FDA) ap. |
businesswire.com |
2025-04-08 12:05:00 |
Czytaj oryginał (ang.) |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Harmony Biosciences Holdings, Inc. (HRMY) And Encourages Shareholders to Reach Out |
NEW YORK, NY / ACCESS Newswire / April 7, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Harmony Biosciences Holdings, Inc. ("Harmony" or "the Company") (NASDAQ:HRMY). Investors who purchased Harmony securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/HRMY. |
accessnewswire.com |
2025-04-07 14:00:00 |
Czytaj oryginał (ang.) |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Harmony Biosciences Holdings, Inc. (HRMY) and Encourages Shareholders to Learn More About the Investigation |
NEW YORK, NY / ACCESS Newswire / April 6, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Harmony Biosciences Holdings, Inc. ("Harmony" or "the Company") (NASDAQ:HRMY). Investors who purchased Harmony securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/HRMY. |
accessnewswire.com |
2025-04-06 14:00:00 |
Czytaj oryginał (ang.) |
| Harmony Biosciences Holdings, Inc. (HRMY) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation |
NEW YORK, NY / ACCESS Newswire / April 4, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Harmony Biosciences Holdings, Inc. ("Harmony" or "the Company") (NASDAQ:HRMY). Investors who purchased Harmony securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/HRMY. |
accessnewswire.com |
2025-04-04 14:00:00 |
Czytaj oryginał (ang.) |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Harmony Biosciences Holdings, Inc. (HRMY) and Encourages Investors to Learn More About the Investigation |
NEW YORK, NY / ACCESS Newswire / April 3, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Harmony Biosciences Holdings, Inc. ("Harmony" or "the Company") (NASDAQ:HRMY). Investors who purchased Harmony securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/HRMY. |
accessnewswire.com |
2025-04-03 14:00:00 |
Czytaj oryginał (ang.) |
| Harmony Biosciences Appoints Biotech Leader Ron Philip to Its Board of Directors |
PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced the appointment of Ron Philip to the Company's Board of Directors. Ron Philip is the President and Chief Executive Officer of Orbital Therapeutics. Ron has 30 years of experience building companies, leading organizational growth, and guiding teams through the development, regulatory approval, and commercialization of novel therapies. Prior to Orbital, he was Chief Executive Officer of Spark. |
businesswire.com |
2025-04-03 12:05:00 |
Czytaj oryginał (ang.) |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating Harmony Biosciences Holdings, Inc. (HRMY) And Encourages Investors to Connect |
NEW YORK, NY / ACCESS Newswire / April 1, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Harmony Biosciences Holdings, Inc. ("Harmony" or "the Company") (NASDAQ:HRMY). Investors who purchased Harmony securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/HRMY. |
accessnewswire.com |
2025-04-01 14:00:00 |
Czytaj oryginał (ang.) |
| Bronstein, Gewirtz & Grossman, LLC Encourages Harmony Biosciences Holdings, Inc. (HRMY) Stockholders to Inquire about Securities Investigation |
NEW YORK, NY / ACCESS Newswire / March 31, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Harmony Biosciences Holdings, Inc. ("Harmony" or "the Company") (NASDAQ:HRMY). Investors who purchased Harmony securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/HRMY. |
accessnewswire.com |
2025-03-31 14:00:00 |
Czytaj oryginał (ang.) |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Harmony Biosciences Holdings, Inc. (HRMY) and Encourages Investors to Learn More About the Investigation |
NEW YORK, NY / ACCESS Newswire / March 30, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Harmony Biosciences Holdings, Inc. ("Harmony" or "the Company") (NASDAQ:HRMY). Investors who purchased Harmony securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/HRMY. |
accessnewswire.com |
2025-03-30 14:00:00 |
Czytaj oryginał (ang.) |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Harmony Biosciences Holdings, Inc. (HRMY) and Encourages Stockholders to Learn More About the Investigation |
NEW YORK, NY / ACCESS Newswire / March 26, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Harmony Biosciences Holdings, Inc. ("Harmony" or "the Company") (NASDAQ:HRMY). Investors who purchased Harmony securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/HRMY. |
accessnewswire.com |
2025-03-26 12:00:00 |
Czytaj oryginał (ang.) |
| Harmony Biosciences to Participate in 24th Annual Needham Virtual Healthcare Conference |
PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in a fireside chat at the upcoming 24th Annual Needham Virtual Healthcare Conference on Wednesday, April 9, 2025, at 3:00 p.m. ET. A webcast of the fireside chat will be available on the investor page of the Harmony Biosciences website at https://ir.harmonybiosciences.com/. About Harmony Biosciences Harmony Biosciences is a pharmaceutical com. |
businesswire.com |
2025-03-26 10:05:00 |
Czytaj oryginał (ang.) |
| Bronstein, Gewirtz & Grossman, LLC Encourages Harmony Biosciences Holdings, Inc. (HRMY) Investors to Inquire about Securities Investigation |
NEW YORK, NY / ACCESS Newswire / March 25, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Harmony Biosciences Holdings, Inc. ("Harmony" or "the Company") (NASDAQ:HRMY). Investors who purchased Harmony securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/HRMY. |
accessnewswire.com |
2025-03-25 12:00:00 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harmony Biosciences Holdings, Inc. - HRMY |
NEW YORK, NY / ACCESS Newswire / March 24, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (NASDAQ:HRMY). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accessnewswire.com |
2025-03-24 19:00:00 |
Czytaj oryginał (ang.) |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Harmony Biosciences Holdings, Inc. (HRMY) And Encourages Investors to Reach Out |
NEW YORK, NY / ACCESS Newswire / March 24, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Harmony Biosciences Holdings, Inc. ("Harmony" or "the Company") (NASDAQ:HRMY). Investors who purchased Harmony securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/HRMY. |
accessnewswire.com |
2025-03-24 16:00:00 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harmony Biosciences Holdings, Inc. - HRMY |
NEW YORK, NY / ACCESS Newswire / February 27, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (NASDAQ:HRMY)Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Harmony and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. |
accessnewswire.com |
2025-02-27 11:00:00 |
Czytaj oryginał (ang.) |
| Should Value Investors Buy Harmony Biosciences (HRMY) Stock? |
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. |
zacks.com |
2025-02-26 12:45:39 |
Czytaj oryginał (ang.) |
| Harmony Biosciences Holdings, Inc. (HRMY) Tops Q4 Earnings and Revenue Estimates |
Harmony Biosciences Holdings, Inc. (HRMY) came out with quarterly earnings of $0.85 per share, beating the Zacks Consensus Estimate of $0.74 per share. This compares to earnings of $0.45 per share a year ago. |
zacks.com |
2025-02-25 11:50:47 |
Czytaj oryginał (ang.) |
| Harmony Biosciences Reports Strong 2024 Financial Results and Reiterates 2025 Net Revenue Guidance; Highlights 2025 Catalysts in Sleep/Wake and Fragile X Syndrome Development Programs |
PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced a record $201.3 million in net product revenues for the fourth quarter 2024, and full year 2024 net revenues of $714.7 million, ending the year with $576 million in cash, cash equivalents and investments on the balance sheet. The company has guided 2025 WAKIX® net revenues to $820 - $860 million, targeting a $1B+ opportunity with WAKIX in narcolepsy alone. “2025 is set up to be a transforma. |
businesswire.com |
2025-02-25 09:30:00 |
Czytaj oryginał (ang.) |
| Harmony Biosciences (HRMY) Upgraded to Strong Buy: Here's Why |
Harmony Biosciences (HRMY) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
zacks.com |
2025-02-24 15:05:40 |
Czytaj oryginał (ang.) |
| 5 High Earnings Yield Value Stocks to Buy Amid Market Volatility |
Volatility looms with sticky inflation, a slowing economy and Trump's trade policies. Buy high-earnings-yield stocks like NUS, HRMY, PAHC, DAN and NRG. |
zacks.com |
2025-02-24 11:10:32 |
Czytaj oryginał (ang.) |
| Harmony Biosciences Stock Falls On FDA Setback For Pitolisant In Sleeping Disorder |
On Wednesday, Harmony Biosciences Holdings, Inc. HRMY received a Refusal to File (RTF) letter from the U.S. Food and Drug Administration (FDA) for pitolisant for excessive daytime sleepiness (EDS) in adult patients with idiopathic hypersomnia (IH). |
benzinga.com |
2025-02-19 16:24:00 |
Czytaj oryginał (ang.) |
| Harmony Biosciences Provides Update on the Status of the Supplemental New Drug Application for Pitolisant in Idiopathic Hypersomnia |
PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it received a Refusal to File (RTF) letter from the U.S. Food and Drug Administration (FDA) for pitolisant for the treatment of excessive daytime sleepiness (EDS) in adult patients with idiopathic hypersomnia (IH). Harmony's 2025 net revenue guidance of $820-$860 million remains unchanged. “We are disappointed with this short-term setback, but our long-term strategy for pitolisant in I. |
businesswire.com |
2025-02-19 10:05:00 |
Czytaj oryginał (ang.) |
| HRMY or ONC: Which Is the Better Value Stock Right Now? |
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Harmony Biosciences Holdings, Inc. (HRMY) and BeiGene, Ltd. (ONC). But which of these two stocks is more attractive to value investors? |
zacks.com |
2025-02-17 14:46:24 |
Czytaj oryginał (ang.) |
| Here is Why Growth Investors Should Buy Harmony Biosciences (HRMY) Now |
Harmony Biosciences (HRMY) is well positioned to outperform the market, as it exhibits above-average growth in financials. |
zacks.com |
2025-02-13 15:46:25 |
Czytaj oryginał (ang.) |
| Are Investors Undervaluing Harmony Biosciences (HRMY) Right Now? |
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. |
zacks.com |
2025-02-05 12:45:52 |
Czytaj oryginał (ang.) |
| Wall Street Analysts Predict a 28.98% Upside in Harmony Biosciences (HRMY): Here's What You Should Know |
The average of price targets set by Wall Street analysts indicates a potential upside of 29% in Harmony Biosciences (HRMY). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. |
zacks.com |
2025-01-31 12:55:24 |
Czytaj oryginał (ang.) |
| HRMY vs. RGEN: Which Stock Is the Better Value Option? |
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Harmony Biosciences Holdings, Inc. (HRMY) and Repligen (RGEN). But which of these two stocks presents investors with the better value opportunity right now? |
zacks.com |
2025-01-30 14:41:12 |
Czytaj oryginał (ang.) |
| Harmony Biosciences: Don't Sleep On This Enterprising, Profitable Biotech |
Harmony Biosciences Holdings, Inc.'s Wakix, a first-in-class drug for narcolepsy, has shown strong revenue growth and recent label expansion to pediatric patients, with good future growth potential. Despite past challenges, including a short attack and a failed Phase 3 study, Harmony's stock has rebounded, supported by solid financials and strategic product extensions. Harmony's diversified pipeline, including new indications for pitolisant / Wakix, and other Phase 3 candidates, positions it for significant revenue growth and reduced single-asset risk. |
seekingalpha.com |
2025-01-24 15:05:04 |
Czytaj oryginał (ang.) |
| 4 High Earnings Yield Value Stocks to Buy as Trump Resumes Presidency |
Unlock your portfolio value with high earnings yield value stocks like HRMY, NGVT, GPOR and PBI. |
zacks.com |
2025-01-23 10:31:14 |
Czytaj oryginał (ang.) |
| Should Value Investors Buy Harmony Biosciences (HRMY) Stock? |
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. |
zacks.com |
2025-01-20 12:45:21 |
Czytaj oryginał (ang.) |
| Why Harmony Biosciences (HRMY) Might be Well Poised for a Surge |
Harmony Biosciences (HRMY) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions. |
zacks.com |
2025-01-15 15:21:11 |
Czytaj oryginał (ang.) |
| How Much Upside is Left in Harmony Biosciences (HRMY)? Wall Street Analysts Think 39.48% |
The mean of analysts' price targets for Harmony Biosciences (HRMY) points to a 39.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. |
zacks.com |
2025-01-15 12:55:23 |
Czytaj oryginał (ang.) |
| HRMY or RGEN: Which Is the Better Value Stock Right Now? |
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Harmony Biosciences Holdings, Inc. (HRMY) and Repligen (RGEN). But which of these two companies is the best option for those looking for undervalued stocks? |
zacks.com |
2025-01-14 14:40:19 |
Czytaj oryginał (ang.) |
| BridgeBio, ARS Pharma, Harmony Bio Shine At JPM. But SpringWorks, Beam Take Their Lumps. |
Biotech stocks put up a split showing at JPM, where names like BridgeBio, ARS and Harmony stood out with strong preliminary reports. The post BridgeBio, ARS Pharma, Harmony Bio Shine At JPM. |
investors.com |
2025-01-13 16:22:10 |
Czytaj oryginał (ang.) |
| Levi & Korsinsky Announces an Investigation on Behalf of Harmony Biosciences Holdings, Inc. (HRMY) Shareholders Who May Have Been Affected by Fraud |
NEW YORK, NY / ACCESSWIRE / December 20, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Harmony Biosciences Holdings, Inc. ("Harmony Biosciences Holdings, Inc.") (NASDAQ:HRMY) concerning possible violations of federal securities laws. On March 28, 2023, Scorpion Capital published a report detailing a string of concerns with Harmony's narcolepsy drug, Wakix (pitolisant). |
accesswire.com |
2024-12-20 09:25:00 |
Czytaj oryginał (ang.) |
| Lost Money on Harmony Biosciences Holdings, Inc.(HRMY)? You May Have Been Affected by Fraud- Contact Levi & Korsinsky |
NEW YORK, NY / ACCESSWIRE / December 19, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Harmony Biosciences Holdings, Inc. ("Harmony Biosciences Holdings, Inc.") (NASDAQ:HRMY) concerning possible violations of federal securities laws. On March 28, 2023, Scorpion Capital published a report detailing a string of concerns with Harmony's narcolepsy drug, Wakix (pitolisant). |
accesswire.com |
2024-12-19 09:25:00 |
Czytaj oryginał (ang.) |
| HARMONY BIOSCIENCES TO PRESENT AT THE 43RD ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE |
PLYMOUTH MEETING, Pa. , Dec. 18, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced its participation in the 43rd Annual J.P. |
prnewswire.com |
2024-12-18 10:05:00 |
Czytaj oryginał (ang.) |
| Lost Money on Harmony Biosciences Holdings, Inc.(HRMY)? Contact Levi & Korsinsky Regarding an Ongoing Investigation |
NEW YORK, NY / ACCESSWIRE / December 18, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Harmony Biosciences Holdings, Inc. ("Harmony Biosciences Holdings, Inc.") (NASDAQ:HRMY) concerning possible violations of federal securities laws. On March 28, 2023, Scorpion Capital published a report detailing a string of concerns with Harmony's narcolepsy drug, Wakix (pitolisant). |
accesswire.com |
2024-12-18 09:30:00 |
Czytaj oryginał (ang.) |
| Investors who lost money on Harmony Biosciences Holdings, Inc. should contact Levi & Korsinsky about an ongoing investigation - HRMY |
NEW YORK, NY / ACCESSWIRE / December 17, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Harmony Biosciences Holdings, Inc. ("Harmony Biosciences Holdings, Inc.") (NASDAQ:HRMY) concerning possible violations of federal securities laws. On March 28, 2023, Scorpion Capital published a report detailing a string of concerns with Harmony's narcolepsy drug, Wakix (pitolisant). |
accesswire.com |
2024-12-17 09:25:00 |
Czytaj oryginał (ang.) |
| Harmony Biosciences Holdings, Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - HRMY |
NEW YORK, NY / ACCESSWIRE / December 16, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Harmony Biosciences Holdings, Inc. ("Harmony Biosciences Holdings, Inc.") (NASDAQ:HRMY) concerning possible violations of federal securities laws. On March 28, 2023, Scorpion Capital published a report detailing a string of concerns with Harmony's narcolepsy drug, Wakix (pitolisant). |
accesswire.com |
2024-12-16 09:25:00 |
Czytaj oryginał (ang.) |
| HRMY ALERT - Levi & Korsinsky Has Commenced an Investigation on Behalf of Harmony Biosciences Holdings, Inc. Shareholders Who Lost Money |
NEW YORK, NY / ACCESSWIRE / December 13, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Harmony Biosciences Holdings, Inc. ("Harmony Biosciences Holdings, Inc.") (NASDAQ:HRMY) concerning possible violations of federal securities laws. On March 28, 2023, Scorpion Capital published a report detailing a string of concerns with Harmony's narcolepsy drug, Wakix (pitolisant). |
accesswire.com |
2024-12-13 09:30:00 |
Czytaj oryginał (ang.) |
| Harmony Biosciences Holdings, Inc. Being Investigated on Behalf of Harmony Biosciences Holdings, Inc. Investors. Contact Levi & Korsinsky For Details. |
NEW YORK, NY / ACCESSWIRE / December 12, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Harmony Biosciences Holdings, Inc. ("Harmony Biosciences Holdings, Inc.") (NASDAQ:HRMY) concerning possible violations of federal securities laws. On March 28, 2023, Scorpion Capital published a report detailing a string of concerns with Harmony's narcolepsy drug, Wakix (pitolisant). |
accesswire.com |
2024-12-12 09:25:00 |
Czytaj oryginał (ang.) |
| Levi & Korsinsky Investigates Possible Securities Fraud Violations by Harmony Biosciences Holdings, Inc. (HRMY) |
NEW YORK, NY / ACCESSWIRE / December 11, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Harmony Biosciences Holdings, Inc. ("Harmony Biosciences Holdings, Inc.") (NASDAQ:HRMY) concerning possible violations of federal securities laws. On March 28, 2023, Scorpion Capital published a report detailing a string of concerns with Harmony's narcolepsy drug, Wakix (pitolisant). |
accesswire.com |
2024-12-11 09:25:00 |
Czytaj oryginał (ang.) |
| Did Harmony Biosciences Holdings, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate - HRMY |
NEW YORK, NY / ACCESSWIRE / December 10, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Harmony Biosciences Holdings, Inc. ("Harmony Biosciences Holdings, Inc.") (NASDAQ:HRMY) concerning possible violations of federal securities laws. On March 28, 2023, Scorpion Capital published a report detailing a string of concerns with Harmony's narcolepsy drug, Wakix (pitolisant). |
accesswire.com |
2024-12-10 09:30:00 |
Czytaj oryginał (ang.) |
| Lost Money on Harmony Biosciences Holdings, Inc. (HRMY)? Contact Levi & Korsinsky Regarding an Ongoing Investigation |
NEW YORK, NY / ACCESSWIRE / December 9, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Harmony Biosciences Holdings, Inc. ("Harmony Biosciences Holdings, Inc.") (NASDAQ:HRMY) concerning possible violations of federal securities laws. On March 28, 2023, Scorpion Capital published a report detailing a string of concerns with Harmony's narcolepsy drug, Wakix (pitolisant). |
accesswire.com |
2024-12-09 09:30:00 |
Czytaj oryginał (ang.) |
| Levi & Korsinsky Investigates Possible Securities Fraud Violations by Harmony Biosciences Holdings, Inc. (HRMY) |
NEW YORK, NY / ACCESSWIRE / December 6, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Harmony Biosciences Holdings, Inc. ("Harmony Biosciences Holdings, Inc.") (NASDAQ:HRMY) concerning possible violations of federal securities laws. On March 28, 2023, Scorpion Capital published a report detailing a string of concerns with Harmony's narcolepsy drug, Wakix (pitolisant). |
accesswire.com |
2024-12-06 09:30:00 |
Czytaj oryginał (ang.) |
| Lost Money on Harmony Biosciences Holdings, Inc.(HRMY)? Contact Levi & Korsinsky Regarding an Ongoing Investigation |
NEW YORK, NY / ACCESSWIRE / December 5, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Harmony Biosciences Holdings, Inc. ("Harmony Biosciences Holdings, Inc.") (NASDAQ:HRMY) concerning possible violations of federal securities laws. On March 28, 2023, Scorpion Capital published a report detailing a string of concerns with Harmony's narcolepsy drug, Wakix (pitolisant). |
accesswire.com |
2024-12-05 09:25:00 |
Czytaj oryginał (ang.) |
| Harmony Biosciences Holdings, Inc. (HRMY) Shareholders May Have Been Affected by Fraud- Levi & Korsinsky Investigates |
NEW YORK, NY / ACCESSWIRE / December 4, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Harmony Biosciences Holdings, Inc. ("Harmony Biosciences Holdings, Inc.") (NASDAQ:HRMY) concerning possible violations of federal securities laws. On March 28, 2023, Scorpion Capital published a report detailing a string of concerns with Harmony's narcolepsy drug, Wakix (pitolisant). |
accesswire.com |
2024-12-04 09:25:00 |
Czytaj oryginał (ang.) |
| HARMONY BIOSCIENCES TO PARTICIPATE IN OPPENHEIMER MOVERS IN RARE DISEASE SUMMIT |
PLYMOUTH MEETING, Pa. , Dec. 3, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in a fireside chat at the upcoming Oppenheimer Movers in Rare Disease Summit in New York, NY on Thursday, December 12, 2024, at 9:00 a.m. |
prnewswire.com |
2024-12-03 10:05:00 |
Czytaj oryginał (ang.) |
| HRMY STOCK ALERT: Levi & Korsinsky Notifies Harmony Biosciences Holdings, Inc. Investors of an Ongoing Investigation |
NEW YORK, NY / ACCESSWIRE / November 29, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Harmony Biosciences Holdings, Inc. ("Harmony Biosciences Holdings, Inc.") (NASDAQ:HRMY) concerning possible violations of federal securities laws. On March 28, 2023, Scorpion Capital published a report detailing a string of concerns with Harmony's narcolepsy drug, Wakix (pitolisant). |
accesswire.com |
2024-11-29 10:00:00 |
Czytaj oryginał (ang.) |
| ATTENTION HRMY SHAREHOLDERS: Investors who lost money on Harmony Biosciences Holdings, Inc. are urged to contact Levi & Korsinsky about an ongoing investigation |
NEW YORK, NY / ACCESSWIRE / November 26, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Harmony Biosciences Holdings, Inc. ("Harmony Biosciences Holdings, Inc.") (NASDAQ:HRMY) concerning possible violations of federal securities laws. On March 28, 2023, Scorpion Capital published a report detailing a string of concerns with Harmony's narcolepsy drug, Wakix (pitolisant). |
accesswire.com |
2024-11-26 09:25:00 |
Czytaj oryginał (ang.) |
| Harmony Biosciences Holdings, Inc. (HRMY) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their Rights |
NEW YORK, NY / ACCESSWIRE / November 25, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Harmony Biosciences Holdings, Inc. ("Harmony Biosciences Holdings, Inc.") (NASDAQ:HRMY) concerning possible violations of federal securities laws. On March 28, 2023, Scorpion Capital published a report detailing a string of concerns with Harmony's narcolepsy drug, Wakix (pitolisant). |
accesswire.com |
2024-11-25 09:30:00 |
Czytaj oryginał (ang.) |
| HARMONY BIOSCIENCES TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES |
PLYMOUTH MEETING, Pa. , Nov. 21, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in the following upcoming investor conferences: Citi's 2024 Global Healthcare Conference Location: Miami Tuesday, December 3, 2024 Piper Sandler 36th Annual Healthcare Conference Location: New York City Fireside Chat: Wednesday, December 4, 2024, at 8:30 a.m. |
prnewswire.com |
2024-11-21 10:05:00 |
Czytaj oryginał (ang.) |
| ATTENTION Harmony Biosciences Holdings, Inc. Investors: You May Have Been Affected by Fraud- Contact Levi & Korsinsky to Discuss Your Rights |
NEW YORK, NY / ACCESSWIRE / November 21, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Harmony Biosciences Holdings, Inc. ("Harmony Biosciences Holdings, Inc.") (NASDAQ:HRMY) concerning possible violations of federal securities laws. On March 28, 2023, Scorpion Capital published a report detailing a string of concerns with Harmony's narcolepsy drug, Wakix (pitolisant). |
accesswire.com |
2024-11-21 09:25:00 |
Czytaj oryginał (ang.) |